NCT05166239View on ClinicalTrials.gov

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

December 29, 2023

Study Completion Date

December 31, 2024

Conditions
Hepatocellular CarcinomaPortal Vein Thrombosis
Interventions
PROCEDURE

HAIC

Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.

DRUG

Lenvatinib 1

12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily after HAIC.

DRUG

PD-1 Inhibitors

PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.

DRUG

Lenvatinib 2

12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily.

DRUG

PD-1 inhibitors 2

PD-1 inhibitors injection intravenously or percutaneously every 4 week.

Trial Locations (1)

100142

RECRUITING

Peking Univerisity Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University

OTHER

NCT05166239 - HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT | Biotech Hunter | Biotech Hunter